Abstract | BACKGROUND: METHOD: Nondemented outpatients with stabilized DSM-IV affective illness took 5 mg/day of donepezil for 3 weeks and then increased to 10 mg/day in open trials. Self-rating scales of target symptoms were completed by patients before and 3 to 4 weeks after starting each dose condition. Patients who chose to continue donepezil therapy returned for clinical monitoring every 4 to 8 weeks. RESULTS: Eleven women and 11 men (mean +/- SD age = 45.4+/-8.5 years) completed donepezil trials. Nineteen patients with memory loss rated improvement while taking 5 mg/day of donepezil (p<.001); subsequently, 6 rated further improvement with 10 mg/day (p = .057). Donepezil, 5 mg/day, also reduced ratings of dry mouth (N = 16; p<.001) and constipation (N = 11; p<.05). Side effects included insomnia, nausea, vomiting, and diarrhea; surprisingly, 2 bipolar patients became manic within hours of starting donepezil. Sixteen patients (72%) continued donepezil for an average of 7 months. Consideration of family histories suggested that donepezil response in affective illness may be an early indicator of vulnerability to dementia of the Alzheimer's type. CONCLUSION:
|
Authors | F M Jacobsen, L Comas-Díaz |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 60
Issue 10
Pg. 698-704
(Oct 1999)
ISSN: 0160-6689 [Print] United States |
PMID | 10549687
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Cholinesterase Inhibitors
- Indans
- Piperidines
- Psychotropic Drugs
- Donepezil
|
Topics |
- Adult
- Ambulatory Care
- Cholinesterase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Constipation
(chemically induced, prevention & control)
- Depressive Disorder
(drug therapy)
- Diarrhea
(chemically induced)
- Dizziness
(chemically induced)
- Donepezil
- Drug Administration Schedule
- Female
- Humans
- Indans
(administration & dosage, adverse effects, therapeutic use)
- Male
- Memory Disorders
(chemically induced, drug therapy)
- Middle Aged
- Piperidines
(administration & dosage, adverse effects, therapeutic use)
- Psychotropic Drugs
(adverse effects, therapeutic use)
- Sleep Initiation and Maintenance Disorders
(chemically induced)
- Xerostomia
(chemically induced, prevention & control)
|